Safety, pharmacokinetics and pharmacodynamics of NXC736, a novel sphingosine-1-phosphate receptor modulator.

In 30 seconds

This randomized controlled trial evaluated the safety, pharmacokinetics, and pharmacodynamics of NXC736, a novel sphingosine-1-phosphate receptor modulator, in healthy male participants. NXC736 was well tolerated at doses up to 80 mg, with a favorable safety profile and dose-dependent reductions in absolute lymphocyte counts, peaking at 67.77% for the 80 mg BID dose.

Key findings

• NXC736 was well tolerated up to 80 mg, twice daily for 14 days.
• Mean terminal half-lives of NXC736 ranged from 3.92 to 15.96 hours.
• Maximum percent reductions in absolute lymphocyte counts reached 67.77% at 80 mg BID.

Why it matters

Understanding the safety and pharmacodynamic effects of NXC736 is crucial for its potential use in treating autoimmune diseases, as it may offer a new therapeutic option for managing these conditions.